Corporate Profile

PDF
Print
E-mail
Written by Administrator
Monday, 21 June 2010 20:31

Cancer Vaccines • Hollow Fiber Bioractor Technology • Cell Culture Services

Biovest International, Inc. is a publicly-traded (OTCQB: BVTI), emerging leader in the field of active personalized immunotherapy targeting life-threatening cancers of the blood system, and markets state-of-the-art hollow fiber bio-production instruments, as well as provides custom cell culture services, including contract manufacturing.

Personalized Cancer Vaccines
Our lead product, BiovaxID®, developed in collaboration with the National Cancer Institute (NCI), is a late-stage (Phase III), patient-specific, cancer vaccine, targeting the treatment of follicular non-Hodgkin’s lymphoma, mantle cell lymphoma, and potentially other B-cell blood cancers.  Both follicular lymphoma and mantle cell lymphoma are generally considered to be incurable with an urgent need to improve survival rates.  BiovaxID is believed to be capable of prolonging remissions by enhancing current standards-of-care for the treatment of B-cell lymphomas without the often toxic side-effects associated with other therapies.

Hollow Fiber Bioreactor Technology
Biovest markets a proprietary line of automated hollow fiber bioreactor systems, including the innovative AutovaxID™ which is a production platform for the scalable manufacture of difficult-to-produce biologics including personalized medicines, monoclonal antibodies, cell culture vaccines and therapeutics targeting highly infectious agents.  AutovaxID is the production system used in the manufacture of BiovaxID, Biovest’s personalized cancer vaccine, and is also being evaluated by the U.S. Naval Health Research Center as a novel production system for viral vaccines.

Cell Culture Services
Since 1981, Biovest has been offering its clients a wide range of instrumentation and cell culture contract manufacturing services dedicated to manufacturing clinical grade biological products, including:

  • Cell line stabilization
  • Master and working cell banks
  • Process development and optimization
  • Protein production and purification
  • Downstream processing

 

Proud Members Of:

 
 
 
Last Updated ( Thursday, 15 September 2011 23:16 )

BiovaxID®

Personalized cancer vaccine targeting certain B-cell lymphomas

Patients Organize Petition Drive

Urging for accelerated approval of lymphoma vaccine 

Media Center

Biovest headlines, videos, webcasts and feature articles